Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received a consensus recommendation of “Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $22.67.

Several equities analysts have issued reports on VNDA shares. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 18th. Jefferies Group LLC restated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Piper Jaffray Companies upped their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Thursday, September 14th. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Thursday, September 14th.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same period in the prior year, the company posted $0.01 EPS. The company’s revenue was up 16.7% on a year-over-year basis.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dupont Capital Management Corp acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth $1,322,000. Foundry Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth $2,478,000. Fox Run Management L.L.C. acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth $696,000. Dynamic Technology Lab Private Ltd increased its position in shares of Vanda Pharmaceuticals by 46.3% during the second quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 6,487 shares during the period. Finally, California State Teachers Retirement System increased its position in shares of Vanda Pharmaceuticals by 8.2% during the second quarter. California State Teachers Retirement System now owns 78,040 shares of the biopharmaceutical company’s stock worth $1,272,000 after buying an additional 5,900 shares during the period. Institutional investors own 86.52% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set Vanda Pharmaceuticals Inc. (VNDA) Price Target at $21.83” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://theolympiareport.com/2017/11/01/brokerages-set-vanda-pharmaceuticals-inc-vnda-price-target-at-21-83.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.